Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease ; volume:30 ; number:2 ; year:2021 ; pages:168-177 ; extent:10
Medical principles and practice ; 30, Heft 2 (2021), 168-177 (gesamt 10)

Creator: Essa, Sahar
Al-Attiyah, Raja’a
Siddique, Iqbal
Al-Nakib, Widad

DOI: 10.1159/000511783

URN: urn:nbn:de:101:1-2021042200190324942033

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Essa, Sahar
Al-Attiyah, Raja’a
Siddique, Iqbal
Al-Nakib, Widad

Other Objects (12)

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Identification of Suitable T-Cell Subsets for Personalized Antiviral T-Cell Immunotherapy

Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy

Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era

Compensated horner scheme

Compensated pathogenic deviations

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Identification of Suitable T-Cell Subsets for Personalized Antiviral T-Cell Immunotherapy

Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy

Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era

Compensated horner scheme

Compensated pathogenic deviations

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Identification of Suitable T-Cell Subsets for Personalized Antiviral T-Cell Immunotherapy

Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy

Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era

Compensated horner scheme

Compensated pathogenic deviations

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Identification of Suitable T-Cell Subsets for Personalized Antiviral T-Cell Immunotherapy

Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy

Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era

Compensated horner scheme

Compensated pathogenic deviations

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Identification of Suitable T-Cell Subsets for Personalized Antiviral T-Cell Immunotherapy

Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy

Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era

Compensated horner scheme

Compensated pathogenic deviations

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Identification of Suitable T-Cell Subsets for Personalized Antiviral T-Cell Immunotherapy

Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy

Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era

Compensated horner scheme

Compensated pathogenic deviations

Related objects

Reset password